Shots:
NICE has issued guidance recommending Imcivree (setmelanotide) as a first therapeutic option in patients aged ≥6yrs. with obesity and controlling hunger caused by POMC deficiency, incl. PCSK1 or LEPR deficiency
Imcivree will be funded and accessible for use in the NHS within 90 days through the Highly Specialized Technologies (HST) pathway. The final NICE recommendation was supported by the EMA and MHRA approval as the sole authorized therapy option for rare genetic obesity conditions
NICE continued to work with Health Technology Assessment bodies and payers across the EU to gain Imcivree market access
Ref: GlobalNewswire | Image: Rhythm
